Purpose: To compare luteinizing hormone–releasing hormone (LHRH) agonists with orchiectomy or diethylstil-bestrol, and to compare antiandrogens with any of these three alternatives. Data Sources: A search of the MEDLINE, Cancerlit
Objectives: Testosterone control is an important issue in patients treated with androgen-deprivation...
It is now generally accepted that prostate cancer is the leading form of cancer in men. Current evid...
ANDROGEN DEPRIVATIONthe r apy (ADT; he r e indefined as medical or surgi-cal castration) is the corn...
To develop a clinical practice guideline for the management of men with metastatic, recurrent, or pr...
Only orchiectomy is still commonly used today either as a single therapy or in combination regimens....
Gonadotrophin-releasing hormone (GnRH) agonists are currently the mainstay in the management of adva...
BACKGROUND: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostat...
The introduction of androgen blockade therapy using luteinising hormone-releasing hormone (LHRH)/gon...
Background: Options for lowering testosterone in patients with prostate cancer include bilateral orc...
Prostate cancer is the second most common cause of cancer-related deaths in men, representing a majo...
Background: Options for lowering testosterone in patients with prostate cancer include bilateral orc...
si ha arg en e ne s t ch includes androgen deprivation therapy (ADT) [3,4] and radiation therapy. AD...
Locally advanced prostate cancer is often associated with elevated recurrence rates. Despite the mod...
Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PC...
Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides ...
Objectives: Testosterone control is an important issue in patients treated with androgen-deprivation...
It is now generally accepted that prostate cancer is the leading form of cancer in men. Current evid...
ANDROGEN DEPRIVATIONthe r apy (ADT; he r e indefined as medical or surgi-cal castration) is the corn...
To develop a clinical practice guideline for the management of men with metastatic, recurrent, or pr...
Only orchiectomy is still commonly used today either as a single therapy or in combination regimens....
Gonadotrophin-releasing hormone (GnRH) agonists are currently the mainstay in the management of adva...
BACKGROUND: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostat...
The introduction of androgen blockade therapy using luteinising hormone-releasing hormone (LHRH)/gon...
Background: Options for lowering testosterone in patients with prostate cancer include bilateral orc...
Prostate cancer is the second most common cause of cancer-related deaths in men, representing a majo...
Background: Options for lowering testosterone in patients with prostate cancer include bilateral orc...
si ha arg en e ne s t ch includes androgen deprivation therapy (ADT) [3,4] and radiation therapy. AD...
Locally advanced prostate cancer is often associated with elevated recurrence rates. Despite the mod...
Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PC...
Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides ...
Objectives: Testosterone control is an important issue in patients treated with androgen-deprivation...
It is now generally accepted that prostate cancer is the leading form of cancer in men. Current evid...
ANDROGEN DEPRIVATIONthe r apy (ADT; he r e indefined as medical or surgi-cal castration) is the corn...
_CRUK_141.svg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG